Literature DB >> 9934342

Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

J J Caro1, J L Speckman, M Salas, G Raggio, J D Jackson.   

Abstract

BACKGROUND: Rational medical decisions should be based on the best possible evidence. Clinical trial results, however, may not reflect conditions in actual practice. In hypertension, for example, trials indicate equivalent antihypertensive efficacy and safety for many medications, yet blood pressure frequently remains uncontrolled, perhaps owing to poor compliance. This paper examines the effect of initial choice of treatment on persistence with therapy in actual practice.
METHODS: The authors examined all outpatient prescriptions for antihypertensive medications filled in Saskatchewan between 1989 and 1994 by over 22,000 patients with newly diagnosed hypertension whose initial treatment was with a diuretic, beta-blocker, calcium-channel blocker or angiotensin-converting-enzyme (ACE) inhibitor. Rates of persistence over the first year of treatment were compared.
RESULTS: After 6 months, persistence with therapy was poor and differed according to the class of initial therapeutic agent: 80% for diuretics, 85% for beta-blockers, 86% for calcium-channel blockers and 89% for ACE inhibitors (p < 0.001). These differences remained significant when age, sex and health status in the previous year were controlled for. Changes in the therapeutic regimen were also associated with lack of persistence.
INTERPRETATION: A relation not seen in clinical trials--between persistence with treatment and initial antihypertensive medication prescribed--was found in actual practice. This relation also indicates the importance of real-world studies for evidence-based medicine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9934342      PMCID: PMC1229944     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  22 in total

1.  Use of prescription-refill records to assess patient compliance.

Authors:  R A Hamilton; L L Briceland
Journal:  Am J Hosp Pharm       Date:  1992-07

Review 2.  Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

Authors:  S E Andrade; A M Walker; L K Gottlieb; N K Hollenberg; M A Testa; G M Saperia; R Platt
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

3.  Identification of the noncompliant hypertensive patient.

Authors:  E C Nelson; W B Stason; R R Neutra; H S Solomon
Journal:  Prev Med       Date:  1980-07       Impact factor: 4.018

4.  The patient's view of hypertension and compliance.

Authors:  C M Sharkness; D A Snow
Journal:  Am J Prev Med       Date:  1992 May-Jun       Impact factor: 5.043

5.  Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program.

Authors:  D M Black; R J Brand; M Greenlick; G Hughes; J Smith
Journal:  J Gerontol       Date:  1987-09

6.  Correlates of nonadherence to hypertension treatment in an inner-city minority population.

Authors:  S Shea; D Misra; M H Ehrlich; L Field; C K Francis
Journal:  Am J Public Health       Date:  1992-12       Impact factor: 9.308

7.  'White-coat' hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care.

Authors:  S D Pierdomenico; A Mezzetti; D Lapenna; M D Guglielmi; M Mancini; L Salvatore; T Antidormi; F Costantini; F Cuccurullo
Journal:  Eur Heart J       Date:  1995-05       Impact factor: 29.983

8.  Intentional prescription nonadherence (noncompliance) by the elderly.

Authors:  J K Cooper; D W Love; P R Raffoul
Journal:  J Am Geriatr Soc       Date:  1982-05       Impact factor: 5.562

9.  Patient compliance with antihypertensive medication.

Authors:  J C Hershey; B G Morton; J B Davis; M J Reichgott
Journal:  Am J Public Health       Date:  1980-10       Impact factor: 9.308

10.  Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population.

Authors:  J K Jones; L Gorkin; J F Lian; J A Staffa; A P Fletcher
Journal:  BMJ       Date:  1995-07-29
View more
  95 in total

1.  Managing hypertension in patients with renal disease and diabetes.

Authors:  A Bell
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

2.  Patient compliance with drug therapy for diabetic nephropathy.

Authors:  D Hughes; B Manns
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

3.  Managing hypertension in patients with renal disease and diabetes.

Authors:  R Grad; S Hanley
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

4.  Access to the morning-after pill in BC.

Authors:  B Osmond
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

5.  Access to the morning-after pill in BC.

Authors:  W D Gutowski
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

Review 6.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 7.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 8.  Adverse events, compliance, and changes in therapy.

Authors:  R Düsing
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 9.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

10.  First-line drugs for hypertension.

Authors:  J D Spence
Journal:  CMAJ       Date:  2001-01-23       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.